NAD+100 mg per vial
- Formula
- C21H27N7O14P2
- Molar mass
- 663.4 g/mol
- CAS number
- 53-84-9
- Class
- Dinucleotide coenzyme (oxidized form), not a peptide; the INN name is nadide
NAD+ / MOTS-c / 5-Amino-1MQ Blend
This vial holds 100 mg of NAD+, 10 mg of MOTS-c and 10 mg of 5-Amino-1MQ, a 10:1:1 vendor stack sold as MitoPrime.
Blend calculations, explained
A fixed-ratio blend requires component-aware arithmetic. Vial composition is kept separate from target amounts so component strengths are never presented as dose suggestions.
Per-component concentration math
Choose the exact vial variant. The Advanced Blend workspace prefills each component and calculates every component concentration from one shared prepared volume.
Vial strength is not a target amount
Each listed number identifies how much of one component is present in the full vial. It does not establish how much of the blend to draw or how often.
How to read the dosing on this page
Blend-level rows
Reported protocols describe how sources reconstitute and draw this vial as a whole, each tied to where it was said.
Component rows
Each peptide's own page reports what studies and guides describe for it alone; the leading rows are repeated below.
One draw, every component
The ratio is fixed by the vial, so a draw sized for one component sets the amount of all the others at the same time.
Molecular profile of each component
NAD+ / MOTS-c / 5-Amino-1MQ Blend is 3 peptides in one vial. Each profile below is PubChem's record for that peptide, read from its own library page; the vial amount is what the label states for this blend, not an amount per draw.
MOTS-c10 mg per vial
- Formula
- C101H152N28O22S2
- Molar mass
- 2,174.6 g/mol
- CAS number
- 1627580-64-6
- Amino acids
- 16
- Sequence
- Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg-OH
- Class
- 16-residue mitochondrial-derived peptide encoded by a short open reading frame inside the 12S rRNA gene of mitochondrial DNA; synthetic human sequence with free N- and C-termini
5-Amino-1MQ10 mg per vial
- Formula
- C10H11IN2
- Molar mass
- 286.1 g/mol
- CAS number
- 42464-96-0
- Class
- Small-molecule quaternary methylquinolinium cation supplied as the iodide salt; a selective inhibitor of nicotinamide N-methyltransferase (NNMT). Not a peptide: there is no amino acid sequence and nothing to reconstitute by sequence maths.
Reported protocols for NAD+ / MOTS-c / 5-Amino-1MQ Blend
What published studies and recent community write-ups report about amounts, timing and course length. 3 community-reported rows, each linked to its source. These are descriptions of what others report, not instructions, and nothing here is medical advice.
| Context | Dose | Frequency | Route | Course | Source |
|---|---|---|---|---|---|
| Community-reported3 rows | |||||
| Community guide: what a 10-12 mg draw delivers | 10-12 mg of total blend (25-30 units at 3 mL of bacteriostatic water), carrying 8.3-10 mg of NAD+, 833 mcg-1 mg of MOTS-c and 833 mcg-1 mg of 5-Amino-1MQ | Daily or every other day | Subcutaneous | 4-8 week cycle; one vial lasts 10-12 days at daily draws or 20-24 days every other dayNot specified beyond the cycle | Community resource2026 |
| This 2026 guide works through the arithmetic of a 120 mg vial made up with 3 mL (40 mg/mL, 0.4 mg per unit) and compares each component's share with standalone practice: MOTS-c inside its usual range, 5-Amino-1MQ at the floor of its, and NAD+ well under, since the whole vial holds roughly one standalone NAD+ dose. It states that there is no established human dose for the blend, no completed human trial of any of the three compounds and no safety data for the combination, and that every figure is laboratory arithmetic drawn from community logs rather than a protocol. | |||||
| Community dosage schedule: six-week cellular energy protocol | 11 mg of total blend per injection | Daily | Subcutaneous, abdomen or thigh | 6 weeksNot specified | Community resource2026 |
| The same site's schedule page gives a single daily figure and recommends 3 mL of bacteriostatic water for the 120 mg vial, with 1-3 mL described as acceptable and 2-5 minutes of swirling to dissolve. It says the three components cannot be dosed separately once mixed, that the reconstituted vial should be used within roughly 4-6 weeks by vendor guidance or 30 days by its own rule, and that no human or animal trial has tested this exact three-compound combination. The page ranks a vendor at the top, so it is not independent of sellers. | |||||
| Community and vendor practice compiled per component | NAD+ 50-100 mg daily, MOTS-c 5-10 mg per week and 5-Amino-1MQ about 50 mg per day by mouth, as separate components; from a combined vial the split is set by the ratio | NAD+ once daily, often in the morning on an empty stomach; MOTS-c split into daily or alternate-day injections | Subcutaneous for NAD+ and MOTS-c; 5-Amino-1MQ by mouth as a standalone, or injected when it is dissolved into the vial | 4-8 weeks active4-6 weeks off; some repeat 2-3 cycles a year | Community resource2026 |
| This profile labels its figures as unverified community and vendor practice and says a PubMed search finds no study of the three compounds together. It points out that the 50 mg oral figure for 5-Amino-1MQ is vendor marketing with no validated rodent-to-human conversion, that no human exposure data exist for MOTS-c, and that a fixed-ratio vial cannot reproduce these per-component amounts. Its own data did not confirm a pre-blended vial, which the vendor and others do sell. | |||||
How a course is commonly described
- Weeks 1-2Community-reported
Community and vendor protocols for the combined vial describe a 4-8 week active cycle with subjective energy and recovery effects reported in the first two weeks. The page is explicit that there are no controlled human pharmacodynamic data for the combination.
- Weeks 4-8Community-reported
Metabolic or body-composition changes, where anyone tracks them, are placed at weeks 4-8 or later. At 10-12 mg per daily draw a 4-8 week cycle consumes about 3-5 vials, or 1.5-3 on alternate days.
- Off-cycle: 4-6 weeksCommunity-reported
A 4-6 week washout is the reported convention, with some repeating 2-3 cycles a year on the argument that episodic NAD+ restoration may beat continuous dosing. None of this comes from a study of the blend.
- What the component data can and cannot sayCommunity-reported
One guide maps a timeline from the component rodent studies: an acute AMPK and plasma NAD+ response in days 1-3, fat-mass and running-capacity changes in mice after 11 days to 2 weeks, and peak insulin sensitisation in mice by weeks 4-5. It labels these reasoned estimates, not blend data, and notes there is no discontinuation or washout data for MOTS-c or 5-Amino-1MQ at all.
- No study has tested NAD+, MOTS-c and 5-Amino-1MQ together in animals or people; the pairing is argued from mechanism (NAD+ supplies the coenzyme, 5-Amino-1MQ blocks the NNMT enzyme that consumes its precursor, MOTS-c activates AMPK) and nothing more. Each component's own evidence, mostly rodent work, is on its page.
- The 10:1:1 ratio locks the doses together. The whole vial holds about one standalone NAD+ dose, so a draw sized for MOTS-c or 5-Amino-1MQ delivers roughly a tenth of a typical NAD+ injection; one guide describes the product as a MOTS-c and 5-Amino-1MQ vial with a supporting quantity of NAD+.
- NAD+ is the awkward component chemically. Unbuffered NAD+ dissolves to a pH of about 2-3, can gel or fail to dissolve, and stings on injection; a compounding-style guide for NAD+ alone raises the pH to 5-6 with small increments of 4.2% or 8.4% sodium bicarbonate through a vent needle, because the reaction gives off carbon dioxide, and warns not to pass pH 6 where NAD+ degrades faster. That guide covers single-agent NAD+ vials, no source describes buffering this blend, and the vendor page does not say whether its NAD+ is buffered; a separate NAD+ guide notes that buffered products ship with a Tris stabiliser while unbuffered powder reconstitutes at about pH 3-4 and is the form more often linked to stinging.
- 5-Amino-1MQ is a small molecule rather than a peptide and is normally sold as capsules; dissolving it into an injectable blend is a vendor formulation choice with no clinical precedent. The vendor warns that the powder may arrive red or reddish because of this component and calls that normal.
- The vendor publishes a per-lot certificate for this blend (lot NM002: 99.03% purity by HPLC, 120.65 mg measured against 120 mg labelled, sterility and endotoxin passed, tested July 2026). That is the seller's documentation of identity and purity, not evidence about the mixture's stability over weeks in the fridge or its effect in anyone. MitoPrime is also the trademarked name of an unrelated ergothioneine supplement ingredient, and the same composition circulates under other vendor names, so the label, not the name, identifies the product.
Sources for this section (6)
Plus 6 community resources (dosing guides, forum threads and vendor write-ups), reported above but not linked.
Reported protocols by component
What sources report for each peptide on its own. In NAD+ / MOTS-c / 5-Amino-1MQ Blend the vial ratio fixes the proportions, so one draw delivers every component at once and none can be raised without the others. The first rows from each component's table are shown here; its page carries the rest, each linked to its source. Descriptions of what others report, not instructions.
NAD+
- ClinicalOnly published human pharmacokinetic study of intravenous NAD+
- Reported amount
- 750 mg in normal saline, about 2 mg per minute (3 micromoles per minute)
- Frequency
- Single infusion
- Route
- Intravenous over 6 hours, with 0.1% dextrose in the bag
- Course
- One 6-hour session, sampled to 8 hours
- Community-reportedPrescriber-oriented summary of subcutaneous and intravenous practice
- Reported amount
- Subcutaneous: about 20 mg per injection to start, titrated to about 100 mg; maintenance 50-100 mg. Intravenous: 500-1000 mg per day for intensive addiction detox protocols
- Frequency
- 1-3 injections weekly during the initial phase, then weekly or every other week; detox infusions daily
- Route
- Subcutaneous self-injection from a reconstituted 500 mg lyophilized vial, or clinic intravenous drip
- Course
- 4-10 days for detox infusion courses; open-ended for maintenance injections
- PreclinicalRat focal ischemia model, intranasal NAD+
- Reported amount
- 10 mg/kg
- Frequency
- Single dose, given 2 hours after the ischemic onset
- Route
- Intranasal
- Course
- Single dose, assessed at 24 and 72 hours
MOTS-c
- ClinicalCB4211 analog, phase 1a/1b (a modified MOTS-c, not the native peptide)
- Reported amount
- 25 mg (phase 1b)
- Frequency
- Once daily
- Route
- Subcutaneous
- Course
- 4 weeks, with participants housed in the study unit
- Community-reportedCommunity standard protocol
- Reported amount
- 5 mg
- Frequency
- 2-3 times per week
- Route
- Subcutaneous
- Course
- 4-8 weeks
- PreclinicalPreclinical discovery paper, insulin sensitivity and diet-induced obesity
- Reported amount
- 5 mg/kg per day for 7 days (insulin sensitivity studies); 0.5 mg/kg per day for 8 weeks (high-fat diet study)
- Frequency
- Once daily (an acute 4-day twice-daily arm was also run)
- Route
- Intraperitoneal injection
- Course
- 7 days or 8 weeks
5-Amino-1MQ
- Community-reportedVendor capsule listing
- Reported amount
- 50 mg per capsule
- Route
- Oral capsule
- PreclinicalAged mouse muscle injury and regeneration study
- Reported amount
- 5 or 10 mg/kg
- Course
- 1 week after injury at either dose, or 3 weeks after injury at 10 mg/kg
- PreclinicalAged mouse exercise and sarcopenia study
- Reported amount
- 10 mg/kg body weight
- Course
- About 8 weeks (22 to 24 months of age)
What is available now
These fields come from the existing picker, blend catalog and observed presentation data. They are identity and availability context, not evidence of effectiveness.
This vial holds 100 mg of NAD+, 10 mg of MOTS-c and 10 mg of 5-Amino-1MQ, a 10:1:1 vendor stack sold as MitoPrime. The vendor and other research vendors market the 120 mg vial for mitochondrial and metabolic research, pairing a coenzyme, a mitochondrial peptide and a small-molecule NNMT inhibitor; only MOTS-c is actually a peptide. No study has tested the three together in animals or people, so the evidence sits on the component pages, and the fixed ratio means a draw sized for MOTS-c or 5-Amino-1MQ carries only about a tenth of a typical standalone NAD+ dose.
- 1
Entry type
Fixed-ratio blend reference
Kept separate from single-peptide evidence and terminology.
- 2
Evidence status
Structured review queued
No evidence level is assigned until references and study models are reviewed.
- 3
Calculator access
Advanced Blend workspace
Calculator access performs arithmetic; it does not establish an amount or protocol.
- 4
Market presentation data
No reviewed observation on file
The vial label remains the authoritative source for any calculation.
Recorded blend variants
Each number is the vial amount for that component. It is not a per-draw amount.
- NAD+
- 100 mg
- MOTS-c
- 10 mg
- 5-Amino-1MQ
- 10 mg
Sources
3 curated references, each with its journal, year and study model, plus 6 community resources reported but not linked.